Literature DB >> 23190686

Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia.

Stephanie M Perez1, Amiksha Shah, Amber Asher, Daniel J Lodge.   

Abstract

Subcortical dopamine system dysregulation has been suggested to underlie the positive symptoms of schizophrenia. Recent preclinical investigations and human imaging studies have proposed that the augmented dopamine system function observed in schizophrenia patients may be secondary to aberrant hippocampal activity. Thus, we posit that the hippocampus represents a novel therapeutic target for the treatment of schizophrenia. Here we provide evidence of the effectiveness of a unique approach aimed at decreasing hippocampal function in a rodent model of schizophrenia. Specifically, in a rodent model of schizophrenia, we demonstrate that ventral hippocampal (vHipp) deep brain stimulation (DBS) can normalize aberrant dopamine neuron activity and behaviours associated with positive symptoms. In addition, we provide evidence that this approach may also be effective in restoring deficits in cognitive function, often left unaltered by conventional antipsychotic medications. Therefore, we have provided initial preclinical evidence demonstrating the feasibility of hippocampal DBS as a potential novel approach for the treatment of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23190686      PMCID: PMC3685478          DOI: 10.1017/S1461145712001344

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  42 in total

1.  Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory.

Authors:  Susheel Vijayraghavan; Min Wang; Shari G Birnbaum; Graham V Williams; Amy F T Arnsten
Journal:  Nat Neurosci       Date:  2007-02-04       Impact factor: 24.884

2.  Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability.

Authors:  M D S Lapiz; D A Morilak
Journal:  Neuroscience       Date:  2005-11-17       Impact factor: 3.590

3.  Hippocampal deep brain stimulation induces decreased rCBF in the hippocampal formation of the rat.

Authors:  Tine Wyckhuys; Steven Staelens; Bregt Van Nieuwenhuyse; Steven Deleye; Hans Hallez; Kristl Vonck; Robrecht Raedt; Wytse Wadman; Paul Boon
Journal:  Neuroimage       Date:  2010-04-13       Impact factor: 6.556

4.  Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--1. Identification and characterization.

Authors:  A A Grace; B S Bunney
Journal:  Neuroscience       Date:  1983-10       Impact factor: 3.590

5.  Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia.

Authors:  Robert E Featherstone; Zoe Rizos; José N Nobrega; Shitij Kapur; Paul J Fletcher
Journal:  Neuropsychopharmacology       Date:  2006-10-11       Impact factor: 7.853

6.  Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons.

Authors:  S B Floresco; C L Todd; A A Grace
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

7.  The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2005-11-23       Impact factor: 7.853

8.  Electrical stimulation of the hippocampal epileptic foci for seizure control: a double-blind, long-term follow-up study.

Authors:  Ana Luisa Velasco; Francisco Velasco; Marcos Velasco; David Trejo; Guillermo Castro; José Damián Carrillo-Ruiz
Journal:  Epilepsia       Date:  2007-07-18       Impact factor: 5.864

9.  Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia.

Authors:  Vicente Molina; Santiago Reig; Javier Pascau; Javier Sanz; Fernando Sarramea; Juan D Gispert; Rogelio Luque; Carlos Benito; Tomás Palomo; Manuel Desco
Journal:  Psychiatry Res       Date:  2003-11-30       Impact factor: 3.222

10.  The epidemiology of schizophrenia: replacing dogma with knowledge.

Authors:  Simona A Stilo; Robin M Murray
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

View more
  29 in total

Review 1.  Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases.

Authors:  Ashok K Shetty; Adrian Bates
Journal:  Brain Res       Date:  2015-09-28       Impact factor: 3.252

2.  Schizophrenia-Like Phenotype Inherited by the F2 Generation of a Gestational Disruption Model of Schizophrenia.

Authors:  Stephanie M Perez; David D Aguilar; Jennifer L Neary; Melanie A Carless; Andrea Giuffrida; Daniel J Lodge
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

3.  Adolescent stress contributes to aberrant dopamine signaling in a heritable rodent model of susceptibility.

Authors:  Stephanie M Perez; Daniel J Lodge
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-07-10       Impact factor: 5.067

4.  Animal Models of Developmental Neuropathology in Schizophrenia.

Authors:  Nickole Kanyuch; Stewart Anderson
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

5.  Comparative analysis of MBD-seq and MeDIP-seq and estimation of gene expression changes in a rodent model of schizophrenia.

Authors:  Jennifer L Neary; Stephanie M Perez; Kara Peterson; Daniel J Lodge; Melanie A Carless
Journal:  Genomics       Date:  2017-03-29       Impact factor: 5.736

Review 6.  Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropharmacology       Date:  2019-05-08       Impact factor: 5.250

7.  Ketamine induced converged synchronous gamma oscillations in the cortico-basal ganglia network of nonhuman primates.

Authors:  Maya Slovik; Boris Rosin; Shay Moshel; Rea Mitelman; Eitan Schechtman; Renana Eitan; Aeyal Raz; Hagai Bergman
Journal:  J Neurophysiol       Date:  2017-05-03       Impact factor: 2.714

8.  Convergent Inputs from the Hippocampus and Thalamus to the Nucleus Accumbens Regulate Dopamine Neuron Activity.

Authors:  Stephanie M Perez; Daniel J Lodge
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

Review 9.  Cellular and circuit models of increased resting-state network gamma activity in schizophrenia.

Authors:  R S White; S J Siegel
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

Review 10.  Cell-based therapies for the treatment of schizophrenia.

Authors:  Jennifer J Donegan; Daniel J Lodge
Journal:  Brain Res       Date:  2016-08-18       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.